Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies

Journal of Drug Targeting

Volumn 20, Issue 8, 2012, Pages 715-719

  Zhou, Qing Hui ^a   Boado, Ruben J ^a,b   Pardridge, William M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ArmaGen Technologies Inc   (United States)

Author keywords

Bloodbrain barrier; Brain targeting; Pharmacokinetics; Targeted drug delivery

Indexed keywords

HUMAN INSULIN; HUMAN INSULIN RECEPTOR MONOCLONAL ANTIBODY IDURONATE 2 SULFATASE FUSION PROTEIN; HYBRID PROTEIN; IDURONATE 2 SULFATASE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G IDURONATE 2 SULFATASE FUSION PROTEIN; INSULIN RECEPTOR; RECOMBINANT HUMAN INSULIN; SOMATOMEDIN B RECEPTOR; TRANSFERRIN RECEPTOR; TRANSFERRIN RECEPTOR MONOCLONAL ANTIBODY IDURONATE 2 SULFATASE FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CROSS REACTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG TARGETING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEMS; IDURONATE SULFATASE; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED C57BL; RECEPTOR, IGF TYPE 2; RECEPTOR, INSULIN; RECOMBINANT FUSION PROTEINS;

EID: 84864619415     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.712132     Document Type: Article

References (18)

1. Boado RJ, Zhang Y, Zhang Y, Pardridge WM. (2007). Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng, 96, 381-391.
2. Boado RJ, Zhang Y, Wang Y, Pardridge WM. (2009). Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol Bioeng, 102, 1251-1258.
3. Brady RO, Schiffmann R. (2004). Enzyme-replacement therapy for metabolic storage disorders. Lancet Neurol, 3, 752-756.
4. Cheng SH, Smith AE. (2003). Gene therapy progress and prospects: Gene therapy of lysosomal storage disorders. Gene Ther, 10, 1275-1281.
5. Cox TM, Cachón-González MB. (2012). The cellular pathology of lysosomal diseases. J Pathol, 226, 241-254.
6. Daniele A, Tomanin R, Villani GR, Zacchello F, Scarpa M, Di Natale P. (2002). Uptake of recombinant iduronate-2-sulfatase into neuronal and glial cells in vitro. Biochim Biophys Acta, 1588, 203-209.
7. Di Francesco C, Cracco C, Tomanin R, Picci L, Ventura L, Zacchello E, Di Natale P, Anson DS, Hopwood JJ, Graham FL, Scarpa M. (1997). In vitro correction of iduronate-2-ulfatase deficiency by adenovirus-mediated gene transfer. Gene Ther, 4, 442-448.
8. Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC. (2007). Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II. Mol Genet Metab, 91, 183-190.
9. Grubb JH, Vogler C, Sly WS. (2010). New strategies for enzyme replacement therapy for lysosomal storage diseases. Rejuvenation Res, 13, 229-236.
10. Lee HJ, Engelhardt B, Lesley J, Bickel U, Pardridge WM. (2000). Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J Pharmacol Exp Ther, 292, 1048-1052.
11. Lu JZ, Boado RJ, Hui EK, Zhou QH, Pardridge WM. (2011). Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein. Biotechnol Bioeng, 108, 1954-1964.
12. Miebach E. (2005). Enzyme replacement therapy in mucopolysaccharidosis type I. Acta Paediatr Suppl, 94, 58-60; discussion 57.
13. Pardridge WM, Boado RJ. (2012). Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Meth Enzymol, 503, 269-292.
14. Pardridge WM, Kang YS, Buciak JL, Yang J. (1995). Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm Res, 12, 807-816.
15. Skarlatos S, Pardridge WM. (1995). Targeting of an anti-CR3 (CD11b/ CD18) monoclonal antibody to spleen but not brain, in vivo in mice. J Drug Target, 3, 9-14.
16. Wilson PJ, Morris CP, Anson DS, Occhiodoro T, Bielicki J, Clements PR, Hopwood JJ. (1990). Hunter syndrome: Isolation of an iduronate-2- sulfatase cDNA clone and analysis of patient DNA. Proc Natl Acad Sci USA, 87, 8531-8535.
17. Wraith JE. (2001). Enzyme replacement therapy in mucopolysaccharidosis type I: Progress and emerging difficulties. J Inherit Metab Dis, 24, 245-250.
18. Zhou QH, Boado RJ, Lu JZ, Hui EK, Pardridge WM. (2012). Brainpenetrating IgG-iduronate 2-sulfatase fusion protein for the mouse. Drug Metab Dispos, 40, 329-335.